zanamivir
E86054
World Health Organization essential medicine
antiviral drug
influenza drug
neuraminidase inhibitor
pharmaceutical drug
small molecule
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
Observed surface forms (1)
| Surface form | As subject | As object |
|---|---|---|
| Relenza | 0 | 1 |
Statements (56)
| Predicate | Object |
|---|---|
| instanceOf |
World Health Organization essential medicine
→
antiviral drug → influenza drug → neuraminidase inhibitor → pharmaceutical drug → small molecule → |
| administeredAs | dry powder for inhalation → |
| administeredWithDevice | Diskhaler → |
| approvedBy |
Food and Drug Administration
→
surface form:
U.S. Food and Drug Administration
|
| approvedInYear | 1999 (US) → |
| belongsToClass |
antiviral agents against influenza
→
sialic acid analogues → |
| cautionIn |
patients with chronic obstructive pulmonary disease
→
patients with underlying respiratory disease such as asthma → |
| commonAdverseEffect |
cough
→
headache → throat irritation → |
| contraindicatedIn | patients with severe milk protein allergy → |
| developedBy |
Biota Holdings
→
GlaxoSmithKline → |
| discoveredAt | Monash University NERFINISHED → |
| discoveredBy | Mark von Itzstein → |
| effectiveAgainst |
2009 H1N1 influenza A virus
→
oseltamivir-resistant influenza strains (some) → |
| eliminatedBy | renal excretion → |
| hasAdministrationFrequency |
once daily for prophylaxis (typical regimen)
→
twice daily for treatment (typical regimen) → |
| hasATCCode | J05AH01 → |
| hasBioavailability | very low oral bioavailability → |
| hasBrandName |
zanamivir
self-linksurface differs
→
surface form:
Relenza
|
| hasCASNumber | 139110-80-8 → |
| hasChemicalFormula | C12H20N4O7 → |
| hasDrugBankID | DB00558 → |
| hasEliminationHalfLife | approximately 2.5 to 5 hours → |
| hasIUPACName | (2R,3R,4S)-4-guanidino-3-acetamido-2-[(1R,2R)-1,2-dihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid → |
| hasMolarMass | 332.31 g/mol → |
| hasPregnancyCategory | B (US, historical classification) → |
| hasProteinBinding | low protein binding → |
| hasPubChemCID | 60855 → |
| hasRouteOfAdministration |
inhalation
→
intranasal → intravenous → oral (investigational, low bioavailability) → |
| hasUNII | L6O9Y65WGF → |
| inhibits |
influenza A neuraminidase
→
influenza B neuraminidase → |
| isHydrophilic | true → |
| isOn |
World Health Organization Model List of Essential Medicines
→
surface form:
WHO Model List of Essential Medicines
|
| mechanismOfAction | neuraminidase inhibition → |
| seriousAdverseEffect |
allergic reactions
→
bronchospasm → |
| targets | influenza virus neuraminidase → |
| usedFor |
prophylaxis of influenza A infection
→
prophylaxis of influenza B infection → treatment of influenza A infection → treatment of influenza B infection → |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Relenza